The Caris Precision Oncology Alliance Welcomes University Hospitals Seidman Cancer Center

University Hospitals Seidman Cancer Center joins Caris' extensive network of leading cancer institutions and research consortia committed to improving patient outcomes through innovations in precision medicine

IRVING, Texas, July 19, 2023 /PRNewswire/ -- Caris Life Sciences^®(Caris), the leading molecular science and technology company actively developing and delivering innovative solutions to revolutionize healthcare, announced today that University Hospitals (UH) Seidman Cancer Center has joined the Caris Precision Oncology Alliance™ (POA). The POA is a growing network of leading cancer centers and research consortia across the globe that collaborate to advance precision oncology and biomarker-driven research, with its members working together to establish and optimize standards of care for molecular testing through innovative research to improve clinical outcomes for cancer patients. POA members are uniquely positioned to leverage Caris' highly sophisticated AI bioinformatics and machine learning capabilities across the company's massive clinico-genomic database to enable innovative research to improve clinical outcomes for cancer patients.

UH Seidman Cancer Center is the only freestanding cancer hospital in Northeast Ohio, with clinicians and staff dedicated to the prevention, diagnosis and treatment of cancer while researching new and innovative treatment options through clinical trials. UH Seidman Cancer Center is part of the National Cancer Institute (NCI)-designated Case Comprehensive Cancer Center at Case Western Reserve University, one of 53 comprehensive cancer centers in the country. UH Seidman specialists make up 14 cancer-specific teams focused on determining integrated care plans tailored to patient's needs.

"The collective power wrought by combining artificial intelligence (AI) with the brightest oncologic minds and the most extensive cancer profiling database is sure to lead to breakthroughs in cancer care. The academic faculty at University Hospitals Seidman Cancer Center are thrilled to join forces with the Caris Precision Oncology Alliance. This collaborative effort solidifies our reputation as one of the leading cancer research institutions in the world," said Theodoros Teknos, M.D., President and Scientific Director, UH Seidman Cancer Center and the Jane and Lee Seidman Chair in Cancer Innovation.

"It is a pleasure to welcome University Hospitals Seidman Cancer Center to the growing Caris Precision Oncology Alliance network," said Chadi Nabhan, M.D., MBA, FACP, Chairman of the POA. "The researchers, clinicians, and leaders of Seidman Cancer Center share the same vision of the Caris Precision Oncology Alliance, to improve the outcomes of all patients diagnosed with cancer through cutting-edge precision oncology research."

The Caris Precision Oncology Alliance includes 87 cancer centers, academic institutions, research consortia and healthcare systems. These institutions have early access to the extensive database and artificial intelligence platform within Caris to establish evidence-based standards for cancer profiling and molecular testing in oncology. By leveraging the comprehensive genomic, transcriptomic and proteomic profiling available through Caris molecular profiling, Caris seeks to provide this network with the ability to prioritize therapeutic options and determine which clinical trial opportunities may benefit their patients. POA members are also able to integrate with a growing portfolio of biomarker-directed trials sponsored by biopharma. Additionally, POA member institutions have access to the most comprehensive clinico-genomic database in the industry, which includes matched molecular and clinical outcomes data from hundreds of thousands of cancer patients, covering over 1 million data points per patient.

About Caris Life Sciences
Caris Life Sciences^® (Caris) is the pioneer in precision medicine and leading molecular science and technology company actively developing and delivering innovative solutions to revolutionize healthcare and improve patient outcomes. Through comprehensive molecular profiling (Whole Exome and Whole Transcriptome Sequencing) and the application of advanced artificial intelligence (AI) and machine learning algorithms, Caris has created the large-scale clinico-genomic database and cognitive computing needed to analyze and unravel the molecular complexity of disease. This convergence of data and machine learning provides an unmatched resource and the ideal path forward to conduct the basic, fundamental research to accelerate discovery for detection, diagnosis, monitoring, therapy selection and drug development to improve the human condition.

With a primary focus on cancer, Caris' suite of market-leading molecular profiling offerings assesses DNA, RNA and proteins to reveal a molecular blueprint that helps patients, physicians and researchers better detect, diagnose and treat patients. The company's latest advancement, Caris Assure™, is a blood-based, circulating nucleic acids sequencing (cNAS) assay that combines comprehensive molecular analysis (Whole Exome and Whole Transcriptome Sequencing from blood) and serial monitoring – making it the most powerful liquid biopsy assay ever developed.

Headquartered in Irving, Texas, Caris has offices in Phoenix, New York, Tokyo, Japan and Basel, Switzerland. Caris or its distributors provide services in the U.S., Europe, Asia and other international markets. To learn more, please visit CarisLifeSciences.com or follow us on LinkedIn.

About University Hospitals Seidman Cancer Center/Cleveland, Ohio

UH Seidman Cancer Center is the only freestanding cancer hospital in Northeast Ohio, where all clinicians and staff are dedicated to the prevention, diagnosis and treatment of cancer while researching new and innovative treatment options through clinical trials. Nationally ranked cancer care is also available to patients through the 11-county region at 16 community-based locations. Our UH Seidman specialists make up 14 cancer-specific teams focused on determining integrated care plans tailored to patient's needs. UH Seidman Cancer Center is part of the National Cancer Institute (NCI)-designated Case Comprehensive Cancer Center at Case Western Reserve University, one of 53 comprehensive cancer centers in the country. Patients have access to advanced treatment options, ranging from a pioneering stem cell transplant program founded more than 40 years ago and a wide range of immunotherapy to the first and only proton therapy center in northern Ohio for adults and children. Go to UHhospitals.org/Seidman for more information.

About University Hospitals / Cleveland, Ohio
Founded in 1866, University Hospitals serves the needs of patients through an integrated network of 21 hospitals (including five joint ventures), more than 50 health centers and outpatient facilities, and over 200 physician offices in 16 counties throughout northern Ohio. The system's flagship quaternary care, academic medical center, University Hospitals Cleveland Medical Center, is affiliated with Case Western Reserve University School of Medicine, Northeast Ohio Medical University, Oxford University and the Technion Israel Institute of Technology. The main campus also includes the UH Rainbow Babies & Children's Hospital, ranked among the top children's hospitals in the nation; UH MacDonald Women's Hospital, Ohio's only hospital for women; and UH Seidman Cancer Center, part of the NCI-designated Case Comprehensive Cancer Center. UH is home to some of the most prestigious clinical and research programs in the nation, with more than 3,000 active clinical trials and research studies underway. UH Cleveland Medical Center is perennially among the highest performers in national ranking surveys, including "America's Best Hospitals" from U.S. News & World Report. UH is also home to 19 Clinical Care Delivery and Research Institutes. UH is one of the largest employers in Northeast Ohio with more than 30,000 employees. Follow UH on LinkedIn, Facebook and Twitter. For more information, visit UHhospitals.org.

Caris Life Sciences Media Contact:
Lisa Burgner
[email protected]
214.294.5606

University Hospitals Media Contact:
Jeannine A. Denholm
[email protected]
323.633.3528

SOURCE Caris Life Sciences